Avadel pharmaceuticals reports q4 and full year 2019 financial results

Avadel pharmaceuticals reports fourth quarter and full year 2019 financial results.q4 loss per share $0.07.q4 revenue $11 million versus refinitiv ibes estimate of $9.1 million.sees q1 2020 revenue $10 million.revenues for fourth quarter of 2019 were $11.0 million, compared to $20.9 million in the fourth quarter of 2018.cash, cash equivalents and marketable securities were $64.2 million as of december 31, 2019.qtrly loss per share of $0.07.realized over $80 million in cost savings from restructuring and other cost reduction actions.q4 earnings per share view $-0.25 -- refinitiv ibes data.
AVDL Ratings Summary
AVDL Quant Ranking